Pharma Focus Asia

Everest Medicines Enters into Licence Agreement with Kezar Life Sciences

Thursday, September 21, 2023

Everest has recently announced a collaboration and licence agreement with Kezar Life Sciences to develop and commercialise Kezar's lead drug candidate, zetomipzomib, in Greater China, South Korea, and select Southeast Asian countries.

Zetomipzomib is a novel and first-in-class selective inhibitor of the immunoproteasome, designed for the treatment of various autoimmune diseases, including lupus nephritis (LN).

Under the terms of the agreement, Kezar will receive an upfront payment of $7 million, with the potential for additional payments based on the achievement of clinical and commercial milestones, totalling up to $125.5 million. Additionally, Kezar will be eligible for tiered single-digit to low-teens royalties on net sales of products resulting from this collaboration. 

This partnership with Kezar, strengthens Everest's position in renal pipeline and autoimmune diseases in Asia. This collaboration marks an important milestone in the development of zetomipzomib, demonstrating the drug's potential to address severe, chronic autoimmune diseases with a favourable safety and tolerability profile.

Zetomipzomib (KZR-616) is a groundbreaking and innovative immunoproteasome inhibitor, setting the standard as a first-of-its-kind treatment with potential benefits across various autoimmune diseases. Moreover, findings from both Phase 1 and Phase 2 clinical trials have indicated that zetomipzomib boasts a safety record and is well-tolerated, making it a promising candidate for the treatment of severe and persistent autoimmune diseases.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024